Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmEng International, a full-service consulting and contract manufacturing company, has announced that Bert Loveless, CFO of the company, will step down from the official role of CFO effective immediately while providing a transitional period of services to the company for an undetermined period of time.
Subscribe to our email newsletter
As a result, the Court ruled in part that: 1) Diagnostica Stago must cease manufacturing and selling its infringing products, STA-Staclot APC-R kits and STAGEN Kit FVM Mutation, and must cease denigrating advertisements concerning IL’s products, 2) Diagnostica Stago’s inventory of STA-Staclot APC-R kits and STAGEN Kit FVM Mutation may be confiscated for potential future destruction, and 3) Diagnostica Stago must pay IL the sum of EUR2,000,000 (approximately $2,600,000) as an advance on damages for the infringement and unfair competition, plus attorneys’ fees. The court’s decision may be appealed.
IL is the exclusive licensee of two patents, EP 0 608 235 and EP 0 690 991, covering inventions from the world-renowned researcher, Dr. Bjorn Dahlback, relating to the detection of thrombophilia, a coagulation disorder, in human blood. The first patent relates to a method for diagnosing a human blood coagulation disorder called resistance to APC (also known as activated protein C resistance) , while the second patent additionally relates to a method for determining the presence of gene mutations of Factor V, which is one of the causes of thrombophilia.
“Litigation is not our first preference. However, our belief that Diagnostica Stago violated our patent rights and unfairly advertised by disparaging IL’s product, forced us to pursue legal action. We are pleased with the Court’s decision”, said Josep Manent, Chief Executive at IL. “Our excellent HemosIL® and Chromogenix® reagent product line offers a broad spectrum of diagnostic tests, including assays for the detection of APC resistance and factor V Leiden mutations. We are committed to providing current and future customers around the world with these tests, to ensure that all hemostasis labs have access to the very best diagnostic tools for the highest quality patient care.”
IL offers tests for identifying resistance to APC, a cause of thrombophilia. Today, IL offers a comprehensive line of HemosIL reagents for the diagnosis of thrombophilia, including antithrombin, protein C, protein S, activated protein C resistance, factor V Leiden, homocysteine, ThromboPath, and Xpert HemosIL FII & FV molecular. Additionally, HemosIL reagents are available for the management of antiphospholipid syndrome, coagulation factors, von Willebrand disease, fibrinolysis, and general screening and anticoagulant monitoring. Coupled with the ACL family of instruments, IL brings automation to the hemostasis lab. IL is dedicated to providing constant innovation through the highest quality, fully integrated solutions.